Journal
MASS SPECTROMETRY REVIEWS
Volume 39, Issue 5-6, Pages 442-451Publisher
WILEY
DOI: 10.1002/mas.21612
Keywords
predictive preventive personalised medicine; multiomics; body fluids; liquid biopsy; innovative strategy; mass spectrometry; wound healing; glaucoma; cardiovascular; cancer; phenotyping; Flammer syndrome; individualised patient profile; biomarker pattern
Categories
Ask authors/readers for more resources
Liquid biopsy (LB) is defined as a sample of any of body fluids (blood, saliva, tear fluid, urine, sweat, amniotic, cerebrospinal and pleural fluids, cervicovaginal secretion, and wound efflux, amongst others), which can be ex vivo analysed to detect and quantity the target(s) of interest. LB represents diagnostic approach relevant for organ-specific changes and systemic health conditions including both manifested diseases and their prestages such as suboptimal health. Further, experts emphasise that DNA-based analysis alone does not provide sufficient information for optimal diagnostics and effective treatments. Consequently, of great scientific and clinical utility are molecular patterns detected by hybrid technologies such as metabolomic tools and molecular imaging. Future proposed strategies utilise multiomic pillars (generally genome, tanscriptome, proteome, metabolome, epigenome, radiome, and microbiome), system-biological approach, and multivariable algorithms for diagnostic, prognostic, and therapeutic purposes. Current article analyses pros and cons of the mass spectrometry-based technologies, provides eminent examples of a success story from discovery to clinical application, and demonstrates a road-map for the technology-driven paradigm change from reactive to predictive, preventive and personalised medical services as the medicine of the future benefiting the patient and healthcare at large. (c) 2019 Wiley Periodicals, Inc. Mass Spec Rev
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available